Last updated: February 16, 2026
What is NDC 70000-0456?
NDC 70000-0456 refers to a specific drug product identified by the FDA's National Drug Code system. Based on the NDC database, this code corresponds to Ruxolitinib (Jakafi), formulated for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Market Size and Segmentation
Disease Area and Patient Population
- Myelofibrosis: Estimated prevalence in the U.S. is approximately 4,000–6,000 patients per year.
- Polycythemia Vera: About 32,000–33,000 cases in the U.S.
- Graft-versus-host disease: Ruxolitinib approved for steroid-refractory acute and chronic GVHD; incidence varies but estimates around 5,000–8,000 cases annually.
Current Market Share (Pre-Patent Expiry)
Jakafi holds approximately 80% of the prescription market for primary indications. Sales for 2022 totaled roughly $1.5 billion (IQVIA).
Competitive Landscape
- Other JAK inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz)
- Emerging therapies: Several pipeline candidates targeting JAK/STAT pathways.
Pricing and Reimbursement Data
List Price
- The wholesale acquisition cost (WAC) for Jakafi in 2023 is approximately $11,275 per month per 100 mg tablet.
- Average annual cost: roughly $135,300 per patient.
Pricing Factors
- Price varies based on dosage, formulation, and geographic region.
- The drug is often covered by insurance, with patient co-payments depending on formulary status.
Reimbursement Landscape
- Reimbursement through Medicare Part D, private insurers.
- Prior authorization often required for coverage.
Market Projections and Price Trends
Short-term (Next 2 Years)
- No significant price changes expected owing to established reimbursement policies.
- Market remains concentrated; discounting primarily driven by payer negotiations.
Mid-term (3-5 Years)
- Entry of biosimilars is unlikely; patent exclusivity extends until 2027 at least.
- Pricing may decline marginally as volume increases and payer pressure intensifies.
Long-term (Beyond 5 Years)
- Patent expiry anticipated around 2027.
- Potential for biosimilar competition could reduce prices by 30–50%, aligning with biosimilar launches in other high-cost biologics.
- Market penetration of generics could decrease average treatment costs significantly.
Key Factors Influencing Future Prices
| Factor |
Impact on Price |
| Patent exclusivity duration |
Maintains high prices during patent life |
| Biosimilar entry |
Drives price down post-patent |
| Market penetration and volume growth |
Can stabilize or lower prices as volume increases |
| Payer negotiation and formulary placement |
May limit upward price movement |
| Regulatory and policy changes |
Can influence pricing strategies |
Summary of Price Projections
| Year |
Estimated Average Price Per Patient |
Notes |
| 2023 |
$135,300 |
Current market price, no biosimilar competition anticipated |
| 2025 |
$130,000–$135,000 |
Slight decrease expected as market stabilizes and payer negotiations strengthen |
| 2027+ |
$70,000–$100,000 (post-patent expiration) |
Potential biosimilar entry could halve prices; actuals depend on biosimilar market uptake |
Conclusions
The drug identified by NDC 70000-0456, which is Ruxolitinib (Jakafi), commands high pricing driven by patent protections, limited competition, and high-value indications. The market is mature with stable sales but faces impending price erosion due to biosimilar or generic entry once patents expire, likely around 2027.
Key Takeaways
- Jakafi’s current average annual per-patient price is approximately $135,000.
- Market share remains dominant, with limited immediate competition.
- Transition to biosimilars post-2027 could reduce prices by up to 50%.
- Reimbursement policies and payer negotiations remain critical in sustaining premium pricing.
- Market expansion into new indications may influence future volumes but not immediate pricing.
FAQs
-
When does patent protection for Ruxolitinib (Jakafi) expire?
Patent protection is expected to expire around 2027, opening the market to biosimilars.
-
How much could prices drop after biosimilar entry?
Biosimilar competition may reduce prices by 30–50%, depending on market dynamics.
-
What are the main drivers of Jakafi’s current high price?
Patent exclusivity, high therapeutic value, limited competition, and formulary coverage contribute to high prices.
-
Are there any approved biosimilars for Ruxolitinib?
As of 2023, no biosimilars for Ruxolitinib have received FDA approval.
-
What factors could influence the market beyond patent expiration?
New indications, payer negotiations, regulatory policies, and emerging therapeutics can impact market dynamics.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2023). NDA Approvals and Patent Status.
- EvaluatePharma. (2022). Global Sales and Market Trends.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies.
- Legal and patent filings databases.
